TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07579234: Phase III Clinical Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor: Shandong New Time Pharmaceutical Co., LTD · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 261 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07579234 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07579234 Rescue Dossier →